Comparison of clinical findings and CT scan in patients with COVID-19 pneumonia based on disease severity

Sonia Hesam-Shariati  
University of New South Wales

Susan Mohammadi  
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences

Morteza Abouzaripour  
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences

Behzad Mohsenpour  
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences

Bushra Zareie  
Hamadan University of Medical Sciences

Fardin Fathi  
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences

Hana Sheikholeslomzadeh  
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences

mohamad bakhtiar hesam shariati (✉ b.hesamshariati@gmail.com)  
Kurdistan University of Medical Sciences  https://orcid.org/0000-0002-2000-5197

Research Article

Keywords: COVID-19, Computed tomography, SARS-CoV-2, acute respiratory disease, pneumonia, clinical features

DOI: https://doi.org/10.21203/rs.3.rs-639747/v1

License: ☑️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

The SARS-CoV-2 can cause severe pneumonia and highly impact general health. We aimed to investigate different clinical features and CT scan findings of patients with COVID-19 based on disease severity to have a better understanding of this disease. For this purpose, 90 patients with coronavirus were examined retrospectively, which were divided into three categories based on the severity of the disease: mild/moderate, severe, and very severe. It has been shown that mean age and duration of hospitalization of patients increased with increasing the severity of disease. The most common clinical symptoms were shortness of breath, cough, and fever. As the severity of the disease increased from mild/moderate to very severe, there was an increase in neutrophile counts and a decrease in lymphocytes and white blood cells (WBC) showing excessive inflammation associated with severe forms of COVID-19. Subpleural changes (81%) and ground-glass opacification/opacity (GGO) lesions (73%) of the lung were the most common features among CT images of COVID-19 patients, and interlobular septal thickening (10%) was the lowest CT feature among patients. Regarding the affected parts of the lung in COVID-19 patients, bilaterial, peripheral and multiple lesions had the highest prevalence. Overall, it has been shown that clinical, laboratory and CT scan findings vary in COVID-19 patients based on disease severity, which need to be considered carefully in early diagnosis and treatment of this illness.

Introduction

In December 2019, the new coronavirus, which later named acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China. SARS-CoV-2 leads to respiratory problems, which on February 11, 2020 was officially named Coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) [1–3]. Numerous studies have shown that SARS-CoV-2 can contaminate human respiratory epithelial cells via an interplay between viral S protein and Angiotensin-converting enzyme 2 (ACE2) on human cells; therefore, SARS-CoV-2 has a high potential to infect humans [4, 5].

The diagnosis of coronavirus disease is mainly dependent on the results of viral nucleic acid, which has high specificity but low sensitivity. According to a recent study, 50% of patients diagnosed with COVID-19 did not have any fever in the early stages of the disease [6], and even in the first few times of nucleic acid tests, negative results have been reported [5, 7]. Numerous studies have shown that simultaneous use of radiological findings (CT scans) and clinical findings can help in the early detection of COVID-19 [5, 8]. Many efforts have been made to collect documents in this area which showed CT scan of the chest as one of the most important methods in diagnosing COVID-19 pneumonia. Various forms of coronavirus-induced destruction of the lung parenchyma have been reported in radiological images, including fibrous stripes, interlobular septal thickening, irregular solid nodules, and ground-glass opacities [9–11].

However, previous studies have not specifically analyzed both clinical and CT scan findings based on disease severity. To further improve the understanding and early diagnosis of COVID-19, we retrospectively examined 90 patients admitted to hospitals in Sanandaj, Kurdistan Province in Iran and classified them into three groups based on the severity of the disease. Clinical symptoms and features of pulmonary CT imaging were analyzed in each group.

Materials And Methods

Study participants
In this study, 90 patients were diagnosed with COVID-19 in hospitals in Sanandaj, Iran. Inclusion criteria for the patients included the following: (1) Positive epidemiological history of contact with definite or probable case; (2) Detection of SARS-CoV-2 in nucleic acid reverse transcriptase reverse polymerase chain reaction of nose and throat swab (2) Have had at least one CT scan of the lung.

COVID-19 patients were categorized in three different groups based on the severity of their illness: mild/moderate, severe, and very severe. These categories were based on whether the patients were outpatients, hospitalized or admitted to intensive care units (ICU).

Data Collection

Clinical parameters such as age, sex, hospitalization days, underlying diseases and conditions (hypertension, diabetes, heart disease, hypothyroidism, chronic obstructive pulmonary disease (COPD), kidney disease, malignancy, epilepsy and any history of surgery), clinical symptoms, laboratory findings and chest CT scan were collected and evaluated. Data were collected between May 10 and November 5, 2020. Epidemiological, clinical, laboratory and radiological data were obtained through patients’ medical records. We obtained any unavailable data through direct contact with physicians and other health care providers.

Real-time Polymerase Chain Reaction

According to the protocols for monitoring pneumonia caused by COVID-19 infection and instructions for laboratory diagnosis of coronavirus [12, 13], SARS coronavirus (SARS-CoV) was detected using commercial kits or COVID-19 rRT-PCR kit.

Image acquisition

All CT scan images of patients were obtained in supine position using a Siemens CT scan machine. The parameters used for these images included the following: detector collimation widths 64 × 0.6 mm, 128 × 0.6 mm, 64 × 0.6 mm, and 64 × 0.6 mm; and tube voltage 120 kV. The images were reconstructed with a cut-off thickness of 1 mm. The reconstructed images were transferred to the hospital’s image archiving and communication systems (PACS) after processing.

Image evaluation

The reconstructed CT images were transferred to the hospital archive and communication system (PACS) and were examined by a radiologist. Features of CT imaging were focused on the following aspects: (a) Distribution of the lesion: left, right, or bilateral lungs. (B) Lesion site: peripheral, central, or both. (C) Lesion characteristics: crazy paving pattern, linear opacities, interlobular septal thickening, vascular enlargement, consolidation, rounded opacities, diffuse confluent, and patchy, ground-glass opacity, organizing pneumonia, subpleural curvilinear line, reticular pattern, pleural changes, pleural effusion, multiple patchy areas of ground glass opacities and peribronchovascular.

Statistical analysis

Any association between the severity of the disease (mild/moderate, severe, and very severe) and clinical and demographic characteristics was examined. In addition, association between CT scan findings and illness severity as well as the outcome of the disease (death or recovery/discharge) were investigated. For the latter analysis, five
patients were excluded since they were hospitalized at the time of our study. Chi-square tests for qualitative variables and one-way analysis of variance (ANOVA) were used to assess the relationship between disease severity and demographic, clinical, and laboratory findings. All the analysis was conducted in STATA 14 software and a $p$-value less than 0.05 was considered as significant.

Ethics

This research has been approved by the Research Center of Kurdistan University of Medical Sciences with the file number (IR.MUK.REC.1399.019)

Results

Demographic Characteristics of Cases

90 patients with coronavirus were examined in this study. The frequency distribution was the same for both genders. Mean (standard deviation) age of the patients was 60.41 (16.55); (Men = 58.14 (18.14); Women = 62.74 (14.60)) years. The frequency distribution of patients based on the severity of the disease in the three categories of mild/moderate, severe and very severe was 40 (49.38%), 30 (37.04%) and 11 (13.58%), respectively. The mean age of patients slightly increased with increasing severity of the disease from mild/moderate to very severe (Table 1). Overall, 75 (83%), 5 (6%) and 10 (11%) of the patients were treated in an outpatient setting, hospitalized and died respectively. The mean (standard deviation) of hospitalization days was 6.80 (5.33) which were significantly increased ($p$-value = 0.013) with increasing severity of the disease (Table 1).
| Illness severity based on clinical and laboratory findings and demographic characteristics |   |   |   |   |
|----------------------------------------------------------------------------------------|---|---|---|---|
| **Illness severity**                                                                  | Mild/Moderate | Severe | Very severe |  
| Sex; Frequency (%)                                                                    |   |   |   |   |
| Male                                                                                  | 17 (41.46)    | 16 (39.02) | 8 (19.51)    | 0.193 |
| Female                                                                                | 23 (57.50)    | 14 (35.00) | 3 (7.50)     | 0.859 |
| Age; mean (SD)                                                                        | 57.97 (17.14) | 62.10 (15.95)| 65.63 (17.18)| 0.013 |
| Hospitalization days; mean (SD)                                                       | 4.45 (3.30)   | 9.83 (5.65) | 10.60 (7.49) | 0.533 |
| **Initial Symptoms: Frequency (%)**                                                   |   |   |   |   |
| Fever                                                                                 | 29 (59.18)    | 15 (30.61) | 5 (10.20)    | 0.899 |
| Cough                                                                                 | 35 (49.30)    | 26 (36.62) | 10 (14.08)   | 0.533 |
| Sputum                                                                                | 6 (66.67)     | 2 (22.22)  | 1 (11.11)    | 0.533 |
| Muscular Pain                                                                         | 17 (47.22)    | 13 (36.11) | 6 (16.67)    | 0.767 |
| Tachypnea                                                                             | 36 (48.00)    | 28 (37.33) | 11 (14.67)   | 0.523 |
| Laboratory test; mean (SD)                                                            |   |   |   |   |
| WBC (*10^3)                                                                            | 7.36 (10.46)  | 11.23 (16.80)| 12.55 (15.65)| 0.075 |
| Creatinine                                                                            | 1.13 (0.59)   | 1.17 (0.53) | 1.24 (0.87)  | 0.300 |
| AST (U/L)                                                                             | 20.30 (4.97)  | 33.77 (24.09)| 25 (3.61)    | 0.698 |
| Platelet                                                                              | 212 (101.49)  | 213.04 (101.51)| 153.27 (72.37)| 0.694 |
| Lymphocyte                                                                            | 0.28 (0.11)   | 0.35 (0.30) | 0.24 (0.29)  | 0.008 |
| Neutrophil count*10^3 L                                                               | 0.65 (0.13)   | 0.76 (0.19) | 0.84 (0.08)  | 0.035 |
| CRP (mg/L)                                                                            | 22.73 (16.65) | 44.09 (29.90)| 34.67 (30.14)| 0.823 |
| Glucose                                                                               | 145.45 (49.15)| 137.67 (64.45)| 222.63 (108.93)| 0.498 |
| PTT                                     | 29.28 (3.56)  | 30.34 (6.27) | 32.78 (11.03) | 0.332 |
| Prothrombin time                                                                      | 13.28 (3.76)  | 13.51 (3.04) | 13.26 (1.32) | 0.490 |
| LDH (U/L)                                                                             | 608.38 (724.34)| 714.62 (346.81)| 803.00 (397.04)| 0.910 |
| Comorbidities; Frequency (%)                                                          |   |   |   |   |
| Diabetics                                                                             | 5 (35.71)     | 6 (42.86)   | 3 (21.43)    | 0.458 |
| Hypertension                                                                          | 11 (47.83)    | 9 (39.13)   | 3 (13.04)    | 0.970 |
| Cardiovascular disease                                                                | 6 (46.15)     | 5 (38.46)   | 2 (15.38)    | 0.962 |
| COPD                                    | 3 (60.00)     | 1 (20.00)   | 1 (20.00)    | 0.704 |
| Illness severity |   |   | p-value† |
|------------------|---|---|----------|
| Hypothyroidism   | 1 (33.33) | 3 (66.66) | 0 (0.00) | 0.516 |

† p-value from Pearson's chi squared test statistics and one-way ANOVA between illness severity and clinical & demographic characteristics.

Abbreviations: WBC, white blood cell counts; AST, aspartate aminotransferase; CRP, C-reactive protein; LDH, lactate dehydrogenase; COPD, Chronic obstructive pulmonary disease.

Disease Characteristics of Patients

The most common symptoms of the Coronavirus disease were shortness of breath (n = 83; 92.22%), cough (n = 78; 86.67%) and fever (n = 54; 60%), respectively. 17% and 15% of people with symptoms of muscle pain and shortness of breath experienced more severe disease, while the severity of the disease in about 67% and 60% of patients with sputum and fever was mild to moderate. Regarding the underlying diseases, more than 64% of patients with diabetes experienced COVID-19 severely (severe or very severe). This amount of severity of COVID-19 was experienced in 52% of patients with hypertension. The prevalence of patients with COPD or hypothyroidism among patients with coronavirus was 5% and 4% respectively (Table 1). In addition, the prevalence of AIDS, acute kidney disease, history of surgery, malignancy and epilepsy in COVID-19 patients were examined, which were less than 4%

Features on Computed Tomography Images

Examining CT scan of patients showed subpleural sparing with 81.11% and ground-glass opacification/opacity (GGO) with 73.33% as the most common CT manifestation and interlobular septal thickening with 10% as the lowest characteristic among patients with COVID-19 (Table 2). 33%, 18%, 17% of patients with interlobular septal thickening, multiple patchy areas of ground glass opacities and diffuse, respectively, had the highest severity of the disease. In addition, 50% of the individuals with Interlobular septal thickening died, and there was a significant difference between the frequency of this characteristics in deceased and recovered patients (p-value < 0.001). In addition, more than 20% of patients with peribronchovascular and those with signs of viral pneumonia on CT scans have died. On the other hand, all the patients with organizing pneumonia and vascular enlargement recovered. The prevalence of recovery for patients with all the other features on CT scan (Table 2) was more than 80%.
### Table 2
Illness severity and outcome of the disease based on CT scan characteristics

| CT characteristics                  | Frequency (%) | Mild/ Moderate | Severe | Very severe | p-value‡ | Alive (%) | Death (%) | p-value‡ |
|-------------------------------------|---------------|----------------|--------|-------------|----------|-----------|-----------|----------|
| Crazy paving pattern                | 23 (25.66)    | 7 (35.00)      | 10 (50.00) | 3 (15.00)   | 0.308    | 20 (90.91) | 2 (9.09)  | 0.651    |
| Interlobular septal thickening      | 9 (10.00)     | 2 (33.33)      | 2 (33.33) | 2 (33.33)   | 0.329    | 4 (50.00)  | 4 (50.00) | < 0.001  |
| Vascular enlargement                | 18 (20.00)    | 11 (64.71)     | 4 (23.53) | 2 (11.76)   | 0.344    | 16 (100.00)| 0 (0.00)  | 0.105    |
| consolidation                       | 33 (36.67)    | 16 (50.00)     | 11 (34.38) | 5 (15.63)   | 0.875    | 26 (86.67)| 4 (13.33) | 0.740    |
| Rounded opacities                   | 27 (30.00)    | 9 (36.00)      | 12 (48.00) | 4 (16.00)   | 0.267    | 24 (88.89)| 3 (11.11) | 0.898    |
| Diffuse confluent and patchy        | 37 (41.11)    | 17 (50.00)     | 13 (38.24) | 4 (11.76)   | 0.919    | 31 (88.57)| 4 (11.43) | 0.936    |
| Air bronchogram                     | 26 (28.89)    | 14 (53.85)     | 8 (30.77) | 4 (15.38)   | 0.722    | 20 (83.33)| 4 (16.67) | 0.379    |
| Ground-glass opacity                | 66 (73.33)    | 31 (51.67)     | 22 (36.67) | 7 (11.67)   | 0.645    | 55 (87.30)| 8 (12.70) | 0.651    |
| Organizing pneumonia                | 14 (15.56)    | 7 (53.85)      | 6 (46.15) | 0 (0.00)    | 0.285    | 14 (100.00)| 0 (0.00)  |          |
| Subpleural curvilinear line         | 19 (21.11)    | 10 (58.82)     | 6 (35.29) | 1 (5.88)    | 0.510    | 17 (94.44)| 1 (5.56)  | 0.357    |
| Viral pneumonia                     | 11 (12.22)    | 8 (80.00)      | 1 (10.00) | 1 (10.00)   | 0.104    | 8 (80.00) | 2 (20.00) | 0.390    |
| Pleural changes                     | 20 (22.22)    | 9 (52.94)      | 6 (35.29) | 2 (11.76)   | 0.939    | 17 (94.44)| 1 (5.56)  | 0.357    |
| Pleural effusion                    | 18 (20.00)    | 7 (50.00)      | 4 (42.86) | 1 (7.14)    | 0.714    | 15 (93.75)| 1 (6.25)  | 0.447    |
| Multiple patchy areas of ground glass opacities | 49 (54.44)    | 23 (51.11)     | 14 (31.11) | 8 (17.78)   | 0.311    | 39 (82.98)| 8 (17.02) | 0.094    |
| Illness severity          | Outcome of the disease |
|--------------------------|------------------------|
| Peribronchovascular      |                        |
| 17 (18.89)               | 11 (78.57)             |
| 7 (50.00)                | 3 (21.43)              |
| 5 (35.71)                | 0.992                  |
| 2 (14.29)                |                        |
| Diffuse                  |                        |
| 24 (26.67)               | 18 (81.82)             |
| 11 (47.83)               | 4 (18.18)              |
| 8 (34.78)                | 0.817                  |
| 4 (17.39)                |                        |
| Subpleural               |                        |
| 73 (81.11)               | 62 (88.57)             |
| 33 (49.25)               | 8 (11.43)              |
| 24 (35.82)               | 0.714                  |
| 10 (14.93)               |                        |
| Unilateral               | 2 (2.22)               |
| Peripheral               | 83 (92.22)             |
| Central                  | 36 (40.00)             |
| Single                   | 1 (1.11)               |
| Multiple                 | 81 (90.00)             |
| Diffuse                  | 27 (30.00)             |
| 0 (0.00)                 | 4 (40.00)              |
| 0 (0.00)                 |                        |

†: *p*-value from Pearson's chi squared test statistics and one-way ANOVA between illness severity and CT characteristics
‡: *p*-value from Pearson's chi squared test statistics between outcome of the disease and CT characteristics

The frequency distribution of affected parts of the lung in all the patients has been shown in Table 3. It has been revealed that more than 91% of all the patients (both recovered and dead) had peripheral and bilateral lesions and 90% of them had multiple lesions in the lung CT scan. In addition, all the COVID-19 patients who died had bilateral, peripheral, and multiple lesions at the same time.

Table 3
Frequency distribution of affected parts of the lung in coronavirus patients and deceased patients

| Lesion      | COVID-19 group (n = 90) Frequency (%) | Death group (n = 10) Frequency (%) |
|-------------|--------------------------------------|------------------------------------|
| Unilateral  | 2 (2.22)                             | 0 (0.00)                           |
| Bilateral   | 82 (91.11)                           | 10 (100.00)                        |
| Peripheral  | 83 (92.22)                           | 10 (100.00)                        |
| Central     | 36 (40.00)                           | 4 (40.00)                          |
| Single      | 1 (1.11)                             | 0 (0.00)                           |
| Multiple    | 81 (90.00)                           | 10 (100.00)                        |
| Diffuse     | 27 (30.00)                           | 4 (40.00)                          |

Laboratory Abnormalities in COVID-19 Patients

As the severity of the disease increased from mild/moderate to very severe, there was a statistically significantly decrease in lymphocyte counts (*p*-value = 0.008) and increase in neutrophile counts (*p*-value = 0.035). White blood cells (WBC) also showed an increasing trend (*p*-value = 0.075) with increasing the severity of disease. Creatinine, aspartate aminotransferase (AST), C-reactive protein (CRP), mean glucose level, partial thromboplastin time (PTT) and lactate dehydrogenase (LDH) increased with increasing the severity of the disease, while platelets decreased from 212 to 153, although none of these features were statistically significant (Table 1).
Discussion

COVID-19 pneumonia, started in Wuhan, China, declared a public health emergency by the World Health Organization (WHO) on January 30, 2020 [14]. The cause of the infection was a new coronavirus (SARS-CoV-2) that has been reported to cause symptomatic and asymptomatic infections. So far, studies have shown that the main routes of transmission of the virus are respiratory droplets and direct contact. The incubation period of this viral disease is generally reported to be 3–7 days, but can take up to 14 days [15, 16].

In this study, we examined clinical, laboratory and CT scan findings of 90 patients with COVID-19 retrospectively. It has been shown that clinical and CT scan findings of patients were not the same at different ages, and there was a slightly higher mean age in patients with a more severe disease. There was also a direct relationship between the average duration of hospitalization and the severity of the disease. Clinical manifestations can indicate patient's physical condition, and the findings on CT images often indicate clinical severity. Studying clinical features and CT scan images can be useful in understanding the differences in disease features between different age groups which can be useful in clinical diagnosis and treatment decisions. Studies have shown that elderly patients with underlying diseases are more likely to have impaired physical activity and weakened immune systems and therefore more susceptible to the effects of coronavirus [17].

According to studies, the most common symptoms of COVID-19 are fever, cough, and shortness of breath (18). We also found shortness of breath (92.22%), cough (86.67%) and fever (60%) as the most common symptoms in patients. In addition, it has been shown that almost 17% and 15% of people with symptoms of muscle pain and shortness of breath have experienced more severe disease, while the severity of the disease in people with symptoms of sputum and fever was milder than other people.

Several underlying diseases were examined in this study. It has been shown that most of the patients with diabetes and hypertension experienced severe or very severe form of COVID-19. The severity of coronavirus disease based on the type of underlying disease has not been reported previously, but a number of studies have shown that the most common diseases associated with coronavirus are hypertension, diabetes, and coronary heart disease [18, 19]. Fang and his colleagues also showed that the severity of coronavirus disease was higher in people with underlying hypertension, diabetes mellitus, coronary heart disease, and cerebrovascular disease [20]. In addition to underlying diseases mentioned in Table 1, AIDS, acute kidney disease, surgical history, malignant tumors, and epilepsy were examined in this study. However, their prevalence was less than 4%.

In our study, with increasing severity of the disease from mild/moderate to very severe, WBC and neutrophils increased. In a study conducted by Olga Pozdnyakova and his colleagues on 90 patients with COVID-19, it has been concluded that all the patients had significant numerical and morphological changes in WBC and there was also a difference between mild and severe disease. More severe disease was associated with significant increase in neutrophils and lymphopenia, which intensified in very severe patients. The abnormal WBC morphology, which is more prominent in monocytes and lymphocytes, was associated with milder disease and the changes disappeared as the disease progressed [21]. We also observed an indirect relationship between lymphocytes counts and the severity of COVID-19. Our findings confirmed previous studies which reported an increase in neutrophiles and a decrease in lymphocytes in severe or non-survival COVID-19 patients which might be due to severe inflammation caused by COVID-19 (23, 24).

In terms of CT characteristics, subpleural changes had the highest frequency (81%) in patients with COVID-19 (Table 2). GGO with 73% was the second noticeable imaging finding (Table 2), indicating that coronavirus
Pneumonia is mainly based on interstitial lung secretion [10, 22]. This means that the pathological mechanism of this disease (coronavirus) is through dilatation and occlusion of alveolar septal capillaries, fluid secretion in the alveolar cavity, and interstitial edema of the leaflet blade [23, 24]. There was not a significant association between subpleural lesions or GGO and the severity or outcome of the disease in this study (Table 2).

Studies have shown that patients with the highest severity of COVID-19 have features such as thickening of the interlobular septum, several areas of ground glass opacity, and diffusion on CT scan images. In addition, the frequency distribution of affected parts of the lung in these patients is more in the form of peripheral lesions [24]. In this study, it was also found that most of the patients with characteristics such as interlobular septal thickening, multiple patchy areas of ground glass opacities and diffuse in CT scan images, had severe or very severe form of the disease (Table 2).

It seems that coronavirus tend to colonize in bilateral and peripheral areas and in the form of multiple lesions (Table 3). In all deceased individuals, bilateral, peripheral, and multiple lesions were observed. Previous studies also revealed bilateral and peripheral involvement and GGO as the most common CT abnormalities in COVID-19 patients (28). There is a strong correlation between different age groups, disease severity and number of affected lobes (27). We also observed that the average age of patients slightly increases with increasing severity of the disease. The lungs of elderly patients are more involved in interstitial changes, which may indicate that the lungs of the elderly are more affected by viral infections and the viruses spread easily in them [25, 26].

**Conclusion**

It has been shown that clinical, laboratory, and CT scan findings in COVID-19 are different based on the severity of the disease. A higher count of neutrophiles compared to lymphocytes were revealed in more severe forms of the disease. GGO and subpleural were the most common CT scan features. Lesions were multiple and mostly affected bilateral and peripheral parts. Underlying diseases also impact the severity of COVID-19 and should be considered. Overall a better understanding of these differences can be useful in the timely and effective diagnosis and treatment of patients with coronavirus. Most importantly in elderly, whose conditions are more likely to be more severe, CT scan and clinical features can provide important information for early diagnosis and treatment.

**Declarations**

**Acknowledgements**

The authors thank all the teaching and medical staff of Kurdistan University of Medical Sciences for their effort in eradicating the virus around the clock.

**Authors’ contributions**

MBHS and SHS supervised the study and wrote the manuscript; HSE and SM collected the clinical data; and MA, BM, and FF analyzed the data and images; SHS reviewed the manuscript. The author(s) read and approved the final manuscript.

**Funding**

No source of funding.
Availability of data and materials

I have presented the data of the patient in the manuscript as a Table. I have submitted the figures separately as figures.

Ethical approval and consent to participate

This research has been approved by the Research Center of Kurdistan University of Medical Sciences with the file number (IR.MUK.REC.1399.019)

Consent for publication

Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article which was approved by the Research Center of Kurdistan University of Medical Sciences.

Competing interests

All authors declare that there is no conflict of interest that prejudices the impartiality of this scientific work.

References

1. Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033–4.
2. Bai Y, et al. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020;323(14):1406–7.
3. Meng H, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect. 2020;81(1):e33–9.
4. Xu X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. 2020;63(3):457–60.
5. Shi H, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet infectious diseases. 2020;20(4):425–34.
6. Alhazzani W, et al., & Du, B.(2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine: p. 1–34.
7. Xie X, Zhong Z, Zhao W. C Zheng, Wang F, J Liu. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology, 2020. 200343.
8. Han X, et al. Novel coronavirus disease 2019 (COVID-19) pneumonia progression course in 17 discharged patients: comparison of clinical and thin-section computed tomography features during recovery. Clin Infect Dis. 2020;71(15):723–31.
9. Wu J, et al. Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features. Investigative radiology. 2020;55(5):257.
10. Zylak CM, et al. Pneumomediastinum revisited. Radiographics. 2000;20(4):1043–57.
11. Zhao X, et al. The characteristics and clinical value of chest CT images of novel coronavirus pneumonia. Clinical radiology. 2020;75(5):335–40.
12. Zhao D, et al. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis. 2020;71(15):756–61.
13. Commission GO.o.N.H., Novel coronavirus pneumonia prevention and control program. 2020.
14. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. Journal of medical virology. 2020;92(4):401–2.
15. Rubin EJ, et al. Medical journals and the 2019-nCoV outbreak. N Engl J Med. 2020;382(9):866.
16. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.
17. Han X, et al. Novel coronavirus pneumonia (COVID-19) progression course in 17 discharged patients: comparison of clinical and thin-section CT features during recovery. Clinical Infectious Diseases; 2020.
18. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020;395(10229):1054–62.
19. Wu C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA internal medicine. 2020;180(7):934–43.
20. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respir Med. 2020;8(4):e21.
21. Pozdnyakova O, et al. Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. Am J Clin Pathol. 2021;155(3):364–75.
22. Lessick J, et al. Multidetector computed tomography predictors of late ventricular remodeling and function after acute myocardial infarction. Eur J Radiol. 2012;81(10):2648–57.
23. Liu J, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. Journal of medical virology. 2020;92(5):491–4.
24. Li W, et al. Clinical and CT features of the COVID-19 infection: comparison among four different age groups. Eur Geriatr Med. 2020;11(5):843–50.
25. Zhu T, et al. A comparative study of chest computed tomography features in young and older adults with corona virus disease (COVID-19). Journal of thoracic imaging; 2020.
26. Baumann BC, MacArthur KM, Baumann JC. Emotional support animals on commercial flights: a risk to allergic patients. The Lancet Respiratory Medicine. 2016;4(7):544–5.